Dr. Mireia Pelegrin obtained her Veterinary degree in Barcelona. She next did a PhD at the Autonomous University of Barcelona focused on the development of transgenic mice as models of diabetes. Then, she moved to France for a post-doctoral training at the Institute of Molecular Genetics of Montpellier to work in the development of gene and cell therapy approaches for in vivo production of therapeutic monoclonal antibodies (mAbs), project that led to two international patents. In 2000, Dr. Pelegrin became Senior Researcher at the CNRS in the same institute where she was a Project leader of a research program on antiviral immunotherapies. She has a long-term experience in the study host-pathogens interactions as well as in antiviral immunotherapies. She has pioneered the proof-of-concept that monoclonal antibody-based immunotherapies can induce long-term protective adaptive immune responses (vaccine-like effects). She has published over 40 articles in the field of immunovirology and antiviral immunotherapies. Dr. Pelegrin recently moved to the Institute for Regenerative Medicine and Biotherapies of Montpellier to lead the group “Antibodies and Immunomodulation”. Her current work aims at deciphering and harnessing antibody-mediated immunomodulation mechanisms for therapeutic strategies.